Navigation Links
Peregrine Pharmaceuticals Presents Promising Antiviral Data at 2009 Chemical and Biological Defense Science & Technology Conference
Date:11/18/2009

the full $44.4 million awarded under the federally funded program, the risk that bavituximab will not achieve broad-spectrum anti-viral effects, the risk that PS-targeting antibodies will not be less susceptible to viral mutations and the risk that the results of clinical trials will not correlate to the preclinical study results. It is important to note that the company's actual results could differ materially from those in any such forward-looking statements. Factors that could cause actual results to differ materially include, but are not limited to, uncertainties associated with completing preclinical and clinical trials for our technologies; the early stage of product development; the significant costs to develop our products as all of our products are currently in development, preclinical studies or clinical trials; obtaining additional financing to support our operations and the development of our products; obtaining regulatory approval for our technologies; anticipated timing of regulatory filings and the potential success in gaining regulatory approval and complying with governmental regulations applicable to our business. Our business could be affected by a number of other factors, including the risk factors listed from time to time in the company's SEC reports including, but not limited to, the annual report on Form 10-K for the year ended April 30, 2009 and the quarterly report on Form 10-Q for the quarter ended July 31, 2009. The company cautions investors not to place undue reliance on the forward-looking statements contained in this press release. Peregrine Pharmaceuticals, Inc. disclaims any obligation, and does not undertake to update or revise any forward-looking statements in this press release.

    Contacts:
    GendeLLindheim BioCom Partners
    Investors                           Media
   '/>"/>
SOURCE Peregrine Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Peregrine Pharmaceuticals Reports Positive Results From Phase II Bavituximab Lung Cancer Trial
2. Peregrine Pharmaceuticals Reports Advances in Bavituximab Clinical Program
3. Peregrine Pharmaceuticals to Present at the Rodman & Renshaw 11th Annual Healthcare Conference
4. Peregrine Pharmaceuticals to Report First Quarter FY 2010 Financial Results
5. Peregrine Pharmaceuticals to Present at the Jesup & Lamont 2009 Growth Stock & National Sales Conference
6. Peregrine Pharmaceuticals Licenses Anti-VEGF Antibodies to Affitech
7. Peregrine Awarded European Patent for Innovative Labeling Technology Featured in New Study in The Journal of Nuclear Medicine
8. Data Presented at Society of Nuclear Medicine 2009 Annual Meeting Supports Potential of Peregrines Cotara(R) for the Treatment of Brain Cancer
9. Peregrine Pharmaceuticals Presents Promising Data From Its Phase II Bavituximab Breast Cancer Trial at 2009 ASCO Annual Meeting
10. Clinical Data on Peregrines Bavituximab Cancer Program to Be Discussed in Two Presentations at 2009 ASCO Annual Meeting
11. Peregrine Pharmaceuticals Reports Positive Data in Second Phase II Bavituximab Breast Cancer Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Scottsdale, Arizona (PRWEB) January 15, 2014 ... growth for Scottsdale’s Brain State Technologies®. They saw continued ... University Medical Center who were awarded a $1 million ... papers published in “Brain and Behavior” a peer reviewed ...
(Date:1/15/2014)... Jan. 15, 2014 TaiGen Biotechnology Company, Limited ("TaiGen") ... with R-Pharm, a leading Russian pharmaceutical company, to develop ... Russian Federation , Turkey ... (CIS). Nemonoxacin is a novel antibiotic for the treatment of ...
(Date:1/14/2014)... Histogen, Inc., a regenerative medicine company ... under simulated embryonic conditions, today announced that they have ... Inc. for physician-dispensed aesthetic products containing Histogen’s proprietary multipotent ... is an amendment to the existing license between Histogen ...
(Date:1/14/2014)... EquitiesIQ, a leading informational research provider, ... is an emerging biomedical company acquiring, developing, manufacturing, and ... , Free report download: http://equitiesiq.com/reports/alliqua/ , In ... team and Board, which launched the company’s new strategy ...
Breaking Biology Technology:Dynamic Innovative Technology Showcased at Scottsdale Company’s Open House 2Dynamic Innovative Technology Showcased at Scottsdale Company’s Open House 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 2TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 4Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 2Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 3EquitiesIQ Initiates Coverage of Alliqua, Inc. 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 3
... Having judged last years a success, the ... opened the second annual Wisconsin Governor's Business Plan ... ,Interested businesses will submit 250-word business proposals within one ... and business services. The proposals will be accepted until ...
... open Thursday , Madison, Wis. The UW-Madison ... advances in nanotechnology, run by the university and Milwaukees ... December 16 during a campus open house, with parking in ... as the manufacture of tiny robots, has led to many ...
... Gateway Technical College has almost finished ... Advanced Career Education Program , and already it has gained ... its ideas. , ,The college receieved a grant on Tuesday ... part by the success of its partnership program. The funds ...
Cached Biology Technology:Governors business-plan competition starts another round 2Governors business-plan competition starts another round 3Tech Digest: Nanotechnology, GE Healthcare, NovaMed, PhysioGenix 2Gateway Technical College pilots IBM training program 2
(Date:7/10/2014)... business incubator, received a $1.4 million federal grant to ... staunch bleeding during brain surgery. , Surgeons can spray ... bio-polymer solutions in the gel will cohere and control ... The gel can shorten an intracranial surgery by 30- ... the patient,s skull to be open and less anesthesia, ...
(Date:7/10/2014)... today that Courtney Aldrich, Ph.D., will head the ... as editor-in-chief. With the first issue slated for ... meet a growing demand for a place to ... vision is to develop a journal focused on ... science that advances the field and lays the ...
(Date:7/10/2014)... with a cardiac pacemaker, a low sense of self-competence ... a study in the July Journal of ... of the Society for Developmental and Behavioral Pediatrics ... Williams & Wilkins , a part of Wolters ... protective factor against lower health-related quality of life in ...
Breaking Biology News(10 mins):A start-up at NJIT develops bleeding-control gel for brain surgery 2ACS Infectious Diseases: Unique chemistry journal names editor 2For children with pacemakers, 'self-competence' affects quality of life 2
... The next time you,re outdoors, see if you can spot the ... an easy task trees there are few and far between, ... In the temperate Northeast, dense forests make the exercise a bit ... sequoias often reach higher than the eye can estimate. Knowing ...
... The United States joined more than 50 countries Thursday ... to better track vessels engaged in illegal, unreported and ... highly migratory species. Annual global economic losses due to ... $23 billion. This action is a first step ...
... This release is available in French . ... Neanderthals and is found exclusively in people outside Africa, according ... of the Department of Pediatrics at the University of Montreal ... in the July issue of Molecular Biology and Evolution. ...
Cached Biology News:MIT: The tallest tree in the land 2MIT: The tallest tree in the land 3US joins over 50 nations in adopting recommendation to list vessels engaged in illegal fishing 2US joins over 50 nations in adopting recommendation to list vessels engaged in illegal fishing 3Genetic research confirms that non-Africans are part Neanderthal 2
... All MagCellect Ferrofluid products perform ... with R&D Systems MagCellect Magnet. ... this neodymium iron boron permanent ... x 75 mm test tubes ...
... 2'-O-Methyltransferase converts Cap 0 (or Cap 0-like) ... 1 structure has been shown to increase ... 50%. This improvement is seen in Cap ... Capping System as well as those Cap ...
Request Info...
Form: Ready to use Applications: Western Blot, ELISA...
Biology Products: